Newsroom
Its Greenville, S.C., Manufacturing Plant
Tuesday, May 16, 2006
ROCHESTER, N.Y. - Bausch & Lomb is working with the U.S. Food and Drug Administration to address the agency's observations and take immediate, appropriate corrective actions after FDA's inspection of Bausch & Lomb's manufacturing plant and distribution facility in Greenville, S.C. The inspection began March 22 and ended May 15.
The agency said none of the observations appear to be related to the outbreak of Fusarium keratitis, a rare eye infection reported in fewer than 200 contact lens wearers worldwide to date, many of whom had used MoistureLoc, a lens solution made at the Greenville plant. Bausch & Lomb communicated promptly and directly with the agency regarding reports the Company received about Fusarium infections. The Company permanently recalled MoistureLoc and will no longer manufacture the formulation. There was no evidence found of product contamination at the Greenville facilities.
Bausch & Lomb is committed to continuous improvement in its operations and to maintaining its operations in compliance with all regulatory requirements and good manufacturing practices.
Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Founded in 1853, the Company is headquartered in Rochester, New York. Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 12,400 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com . Copyright Bausch & Lomb Incorporated.
® / TM denote trademarks of Bausch & Lomb Incorporated.
